Background Ovarian cancer is the sixth most common cancer and seventh most common cause of cancer death in women worldwide. Three-quarters of women present when the disease has spread throughout the abdomen (stage III or IV) and treatment consists of a combination of debulking surgery and platinum-based chemotherapy. Although initial responses to chemotherapy are good, most women will relapse and require further chemotherapy and will eventually develop resistance to chemotherapy. PARP (poly (ADP-ribose) polymerase) inhibitors, are a novel type of medication that works by preventing cancer cells from repairing their DNA once they have been damaged by other chemotherapy agents. It is not clear how PARP inhibitors compare to conventional chemotherapy regimens for the treatment of ovarian cancer, with respect to survival, side effects and quality of life. Objectives To determine the benefits and risks of PARP inhibitors for the treatment of epithelial ovarian cancer (EOC).

Analysis 1.1. Comparison 1: Newly diagnosed EOC: PARPi with chemotherapy compared with chemotherapy alone, Outcome Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (Review)

Analysis 2.12. Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 12 Toxicity: grade 3 or 4 allergic reaction/drug hypersensitivity......... Analysis 2.13. Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome